CD8A and neoplasm: This combination therapy has been associated with improved clinical outcomes in patients, indicating that the interplay between CD8+TRM cells and other tumor‐specific CD8+T cell subsets is crucial for orchestrating effective antitumor responses [225] (Figure 4).